Remnant of the liver (REM) (%) was calculated by CT volumetry and the weight of resected specimens. In addition to general blood test, ICG elimination rate (ICG K) was measured preoperatively. PHLF was defined according to the criteria proposed by International Study Group of Liver Surgery (Surgery. 2011 May;149(5):713-24.) and gradad as A, B, or C. Liver fibrosis was graded as F0 to F4 by METAVIR score. The ability of SWV, ICG K, and general hematological/biochemical factors for the prediction of PHLF was compared by receiver operating characteristic (ROC) BMS-777607 purchase analysis. The mean SWV was 1.31, 1.40, 1.60, 1.80,

and 2.80 for F0 to F4, respectively. Grade A PHLF occurred in 21 patients (9%) whereas grade B in 16 patients (7%) and grade C in 4 patients (2%). The area under the curve (AUC) of the ROC curve (AUROC) for the prediction of PHLF was (in descending order) 0.704 for SWV, 0.698 for hyaluronic acid (HA), 0.674 for PT-INR, 0.673 for platelet count (PLT), 0.664 for T-bil and 0.619 for ICG K. AUROC for grade B or C PHLF was 0.783 for SWV, 0.754 for HA, 0.722 for PLT, 0.676 for ICG K, 0.636 for PT-INR and 0.621 for T-Bil. The stepwise variable selection with minimum BIC’s method identified 3 significant factors associated

with PHLF. They were 1/ SWV, 1/REM and T-Bil. By logistic regression analysis, we established a risk index for PHLF as (-2.23521458260909) www.selleckchem.com/products/pd-0332991-palbociclib-isethionate.html + (-4.49647423960785) * 1/SWV + 1.24494777087502 * 1/REM + 1.91138407348298 * T-Bil. AUROC of the risk index for PHLF was 0.799 for all grade and 0.835 for grade B or C, which were better Aldol condensation than AUROC of any single preoper-ative factors. In conclusion, risk assessment incorporating LSM is useful

for the prediction of PHLF. Disclosures: The following people have nothing to disclose: Gen Yamamoto, Kojiro Taura, Yukinori Koyama, Kazutaka Tanabe, Takahiro Nishio, Yukihiro Okuda, Etsuro Hatano, Shinji Uemoto Background: Recent attention has focused on the impact of donor-specific HLA antibodies (DSA) in deceased donor liver transplantation (DDLT). With less ischemia, improved donor selection and more controlled procedures, living donor liver transplantation (LDLT) may speculatively lead to less DSA formation and/or impact on patient and graft outcomes. Aim: To compare the incidence and impact of DSA in LDLT vs. DDLT Methods: The A2ALL biorepository was probed for primary LDLT and DDLT recipients with available serum samples pre-(immediately prior to implantation) and post-LT (∼3 months). Samples positive for panel reactive antibodies were tested for DSA (class, titer) using the Luminex platform. We compared the incidence of pre- (preformed) and post- (de novo) LT DSA between LDLT and DDLT and correlated DSA with the following time-dependent endpoints: patient and graft survival, rejection, biliary/vascular complications, HCV recurrence.